keyword
MENU ▼
Read by QxMD icon Read
search

Clear cell carcinoma

keyword
https://www.readbyqxmd.com/read/29923634/radioimmunoimaging-and-targeting-treatment-in-an-immunocompetent-murine-model-of-triple-negative-breast-cancer-using-radiolabeled-anti-pd-l1-monoclonal-antibody
#1
Xiaoxi Pang, Meng Liu, Rongfu Wang, Xuhe Liao, Ping Yan, Chunli Zhang
The overall aim of this study was to evaluate whether iodine-131 radiolabeled monoclonal antibody (mAb) targeting PD-L1 can be used for imaging of PD-L1 expression noninvasively in vivo, and playing synergistic effect combined with immunotherapy. Anti-PD-L1 mAb was radiolabeled with iodine-131 (131 I-PD-L1 mAb), and was characterized in vitro. Biodistribution and imaging in vivo were performed periodically. Therapy study was conducted in triple-negative breast cancer bearing BALB/c mice. As results, the labeling efficiencies of 131 I-PD-L1 mAb reached 80 % ± 3 %, with radiochemical purity was 97 % ± 1 %...
June 20, 2018: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29921512/a-phase-ii-evaluation-of-sunitinib-in-the-treatment-of-persistent-or-recurrent-clear-cell-ovarian-carcinoma-an-nrg-oncology-gynecologic-oncology-group-study-gog-254
#2
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson
OBJECTIVES: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. METHODS: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity...
June 16, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29921232/cysteine-boosters-the-evolutionary-adaptation-to-cocl-2-mimicked-hypoxia-conditions-favouring-carboplatin-resistance-in-ovarian-cancer
#3
Sofia C Nunes, Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Cristiano Ramos, Sofia A Pereira, Jacinta Serpa
BACKGROUND: Ovarian cancer is the second most common gynaecologic malignancy and the most common cause of death from gynaecologic cancer, especially due to diagnosis at an advanced stage, when a cure is rare. As ovarian tumour grows, cancer cells are exposed to regions of hypoxia. Hypoxia is known to be partially responsible for tumour progression, metastasis and resistance to therapies. These suggest that hypoxia entails a selective pressure in which the adapted cells not only have a fitness increase under the selective environment, but also in non-selective adverse environments...
June 19, 2018: BMC Evolutionary Biology
https://www.readbyqxmd.com/read/29917167/androgen-receptor-induces-epha3-expression-by-interacting-with-transcription-factor-sp1
#4
Xiaowei Diao, Xiubin Chen, Yurui Pi, Yu Zhang, Fangfang Wang, Ping Liu, Yanhong Gao, Xiaojun Wang, Sijun Yang, Shan Lu
Erythropoietin‑producing hepatocellular carcinoma cell surface type‑A receptor 3 (EPHA3) has been found to promote the proliferation and survival of prostate cancer (PCa) cell lines and prostate tumor development in nude mice. However, the regulation of EPHA3 in PCa remains largely unknown. This study is aimed to investigate the association between EPHA3 expression and androgen receptor (AR) signaling and the potential mechanism. We determined mRNA and protein levels of EPHA3 and AR signaling‑related genes in the PCa cell line 22Rv1 by reverse transcription‑polymerase chain reaction (RT‑PCR) and western blotting, respectively...
June 18, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29916898/a-case-of-complete-response-to-nivolumab-after-long-term-progression-free-survival-with-tyrosine-kinase-inhibitor
#5
Veronica Mollica, Vincenzo Di Nunno, Beniamino Corcioni, Michelangelo Fiorentino, Elisabetta Nobili, Riccardo Schiavina, Rita Golfieri, Eugenio Brunocilla, Andrea Ardizzoni, Francesco Massari
Nivolumab is an effective and tolerable treatment for metastatic renal cell carcinoma, showing longer median overall survival than everolimus and achieving a good percentage of objective response, stable disease, and prolonged responses. However, very few cases have been reported in the literature of a complete response to nivolumab in the metastatic pretreated setting. Here, we report a case of complete response to nivolumab in II line following sunitinib in a metastatic clear cell renal cell carcinoma with favorable risk according to the IMDC criteria...
June 18, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29915799/a-case-of-severe-encephalitis-while-on-pd-1-immunotherapy-for-recurrent-clear-cell-ovarian-cancer
#6
Morgan Burke, Melissa Hardesty, Wayne Downs
Recurrent clear cell ovarian carcinoma is a difficult to treat condition and early trial data has suggested a possible role for immune checkpoint inhibitors. Nivolumab is an anti-PD-1 immunotherapy that has been used in this setting. While immune related toxicity of these agents has been well described, the occurrence of immune specific neurotoxicity is thought to be rare. We present a case of severe encephalitis while on PD-1 immunotherapy for a recurrent ovarian clear cell cancer and we believe this to be the first such reported case associated with the use of PD-1 inhibitor monotherapy...
May 2018: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29912766/clinical-utility-of-fluorescence-in-situ-hybridization-fish-for-deletion-of-chromosome-3p-in-the-work-up-of-renal-masses
#7
Carmen M Perrino, Jason A Orien, Jason G Tretter, Weiqiang Zhao, Debra L Zynger
Chromosome 3p deletion is a well-established genetic aberration in clear cell renal cell carcinoma (RCC). We aimed to evaluate the clinical utility of 3p fluorescence in situ hybridization (FISH) on formalin-fixed paraffin-embedded tissue in surgical pathology specimens. 3p:3q <0.8 was established as the cut-off for 3p loss. The 2015 Medicare allowable billing rates were used to estimate the cost. Over 2.5 years (2013 to 2015), 3p FISH was performed on 18 cases per year. Among tested cases, 70% (30/43) were nephrectomies and 30% (14/43) metastases...
June 15, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/29912718/pulmonary-sarcomatoid-carcinomas-a-review
#8
Annikka Weissferdt
Pulmonary sarcomatoid carcinomas belong to a group of neoplasms that remain incompletely understood. They are rare tumors of the bronchopulmonary system that incorporate a wide range of neoplasms that by definition contain a sarcomatoid component characterized by spindle or giant cells. Such classification has led to a heterogenous tumor category that includes neoplasms with different clinical, morphologic, and prognostic features. To date, the histopathologic diagnosis of pulmonary sarcomatoid carcinomas does not require the use of ancillary testing and is based on light microscopic criteria alone...
June 15, 2018: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/29912290/accounting-for-differential-variability-in-detecting-differentially-methylated-regions
#9
Ya Wang, Andrew E Teschendorff, Martin Widschwendter, Shuang Wang
DNA methylation plays an essential role in cancer. Differential variability (DV) in cancer was recently observed that contributes to cancer heterogeneity and has been shown to be crucial in detecting epigenetic field defects, DNA methylation alterations happening early in carcinogenesis. As neighboring CpG sites are highly correlated, here, we present a new method to detect differentially methylated regions (DMRs) that uses combined signals from differential methylation and DV between sample groups. We demonstrated in simulation studies the superior performance of the new method than existing methods that use only one type of signals when true DMRs have both...
August 18, 2017: Briefings in Bioinformatics
https://www.readbyqxmd.com/read/29911682/contact-guidance-is-cell-cycle-dependent
#10
Kamyar Esmaeili Pourfarhangi, Edgar Cardenas De La Hoz, Andrew R Cohen, Bojana Gligorijevic
Cancer cell migration is essential for metastasis, during which cancer cells move through the tumor and reach the blood vessels. In vivo , cancer cells are exposed to contact guidance and chemotactic cues. Depending on the strength of such cues, cells will migrate in a random or directed manner. While similar cues may also stimulate cell proliferation, it is not clear whether cell cycle progression affects migration of cancer cells and whether this effect is different in random versus directed migration. In this study, we tested the effect of cell cycle progression on contact guided migration in 2D and 3D environments, in the breast carcinoma cell line, FUCCI-MDA-MB-231...
September 2018: APL bioengineering
https://www.readbyqxmd.com/read/29911113/survival-outcomes-for-advanced-kidney-cancer-patients-in-the-era-of-targeted-therapies
#11
Arpit Rao, Charles Wiggins, Richard C Lauer
Background: Advanced renal cell carcinoma (RCC) results in over 14,000 deaths each year in the United States alone. The therapeutic landscape for advanced RCC changed dramatically with the approval of tyrosine kinase inhibitors (TKI) between 2006 and 2012. A large-scale analysis of survival trends has not been performed in the TKI era to determine their impact on outcomes for advanced RCC patients. Methods: The Surveillance, Epidemiology and End-Results (SEER) database was queried for adult patients with advanced RCC diagnosed between 2000 and 2013...
May 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29910061/potential-impact-of-pd-l1-sp-142-immunohistochemical-heterogeneity-in-clear-cell-renal-cell-carcinoma-immunotherapy
#12
José I López, Rafael Pulido, Jesús M Cortés, Javier C Angulo, Charles H Lawrie
Intratumor heterogeneity (ITH) detection remains a challenge in modern oncology because it can have a direct impact on the success of new therapies. Anti-PD-1/PD-L1 immunotherapy is an emerging treatment modality that is showing great promise for clear cell renal cell carcinoma (CCRCC) patients with advanced disease. Patient selection for such therapy relies upon the immunohistochemical detection of PD-1/PD-L1, however the degree of ITH for these markers among tumor cells and/or inflammatory mononuclear infiltrates remains unknown...
June 12, 2018: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29908944/optimizing-the-role-of-surgery-and-radiotherapy-in-urethral-cancer-based-on-histology-and-disease-extent
#13
Christina H Son, Stanley L Liauw, Yasmin Hasan, Abhishek A Solanki
BACKGROUND: Urethral cancer is rare, with limited data guiding treatment. A national hospital-based registry was used to evaluate the role of local therapy in these patients. METHODS: We performed a retrospective cohort study of patients with T0-4N0-2 M0 urethral cancer (2004-2013). Local therapy was: radiation (RT), surgery (S), or surgery and radiation (S+RT). The Cox proportional hazards model was used to assess the impact of therapy type on overall survival (primary endpoint)...
June 14, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29905933/the-classification-of-pediatric-and-young-adult-renal-cell-carcinomas-registered-on-the-children-s-oncology-group-cog-protocol-aren03b2-after-focused-genetic-testing
#14
Mariana M Cajaiba, Lisa M Dyer, James I Geller, Lawrence J Jennings, David George, Dawn Kirschmann, Stephen M Rohan, Nicholas G Cost, Geetika Khanna, Elizabeth A Mullen, Jeffrey S Dome, Conrad V Fernandez, Elizabeth J Perlman
BACKGROUND: Renal cell carcinomas (RCCs) are rare in young patients. Knowledge of their pathologic and molecular spectrum remains limited, and no prospective studies have been performed to date in this population. This study analyzes patients diagnosed with RCC who were prospectively enrolled in the AREN03B2 Children's Oncology Group (COG). The objective was to classify these tumors with the aid of focused genetic testing and to characterize their features. METHODS: All tumors registered as RCC by central review were retrospectively re-reviewed and underwent additional ancillary studies...
June 15, 2018: Cancer
https://www.readbyqxmd.com/read/29904312/secondary-involvement-of-the-gastrointestinal-tract-by-renal-cell-carcinoma
#15
Daniel S Grosser, He Huang
Secondary involvement of the gastrointestinal (GI) tract by renal cell carcinoma is rare. We undertook a retrospective review of our institution's pathology records from January 2006 to July 2017 and identified eight cases of GI tract involvement by renal cell carcinoma. Sites of involvement included stomach, duodenum, jejunum, ileum, and cecum. Pertinent clinical information was obtained from electronic medical records. The interval from primary resection to identification of GI involvement was often prolonged, averaging 6 years, and mimicked primary GI tract malignancies, with presentations including GI bleeding, abdominal pain, and obstruction...
July 2018: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/29903415/a-multicenter-phase-ii-trial-of-axitinib-in-patients-with-recurrent-or-metastatic-non-clear-cell-renal-cell-carcinoma-who-had-failed-prior-treatment-with-temsirolimus
#16
Inkeun Park, Se Hoon Lee, Jae Lyun Lee
BACKGROUND: The optimal treatment option for non-clear-cell renal cell carcinoma (nccRCC) is not established. We conducted a multicenter phase II trial of axitinib for patients with advanced nccRCC who had failed prior treatment with temsirolimus. PATIENTS AND METHODS: Patients with histologically confirmed metastatic or recurrent nccRCC received 5 mg axitinib twice daily. Prior use of vascular endothelial growth factor pathway inhibitors was not allowed. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate, overall survival, and safety...
May 23, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29902078/leukemia-inhibitory-factor-receptor-suppresses-the-metastasis-of-clear-cell-renal-cell-carcinoma-through-negative-regulation-of-the-yes-associated-protein
#17
Chengyong Lei, Shidong Lv, Hongyi Wang, Chuan Liu, Qiliang Zhai, Shanci Wang, Guixing Cai, Dingheng Lu, Zhen Sun, Qiang Wei
The role of leukemia inhibitory factor receptor (LIFR), which is important in the signal transduction of the interleukin-6 cytokine family, is still undefined in clear cell renal cell carcinoma (ccRCC). Thus, we examined the function and mechanism of LIFR in ccRCC. Low LIFR expression correlated with a poor prognosis and an aggressive tumor phenotype. Moreover, integrated LIFR DNA and mRNA analysis revealed that promoter methylation and copy number variation contributed to the reduced LIFR expression. LIFR knockdown increased 786-O and Caki-2 cell invasion and migration...
June 14, 2018: DNA and Cell Biology
https://www.readbyqxmd.com/read/29901626/curcumin-induces-endoplasmic-reticulum-stress-associated-apoptosis-in-human-papillary-thyroid-carcinoma-bcpap-cells-via-disruption-of-intracellular-calcium-homeostasis
#18
Li Zhang, Xian Cheng, Shichen Xu, Jiandong Bao, Huixin Yu
BACKGROUND: Thyroid cancer is the most common endocrine tumor. Our previous studies have demonstrated that curcumin can induce apoptosis in human papillary thyroid carcinoma BCPAP cells. However, the underlined mechanism has not been clearly elucidated. Endoplasmic reticulum (ER) is a major organelle for synthesis, maturation, and folding proteins as well as a large store for Ca. Overcoming chronically activated ER stress by triggering pro-apoptotic pathways of the unfolded protein response (UPR) is a novel strategy for cancer therapeutics...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29901523/ovarian-carcinoma-histotype-strengths-and-limitations-of-integrating-morphology-with-immunohistochemical-predictions
#19
Martin Köbel, Li Luo, Xin Grevers, Sandra Lee, Angela Brooks-Wilson, C Blake Gilks, Nhu D Le, Linda S Cook
Ovarian carcinoma histotypes are critical for research and patient management and currently assigned by a combination of histomorphology +/- ancillary immunohistochemistry (IHC). We aimed to validate the previously described IHC algorithm (Calculator of Ovarian carcinoma Subtype/histotype Probability version 3, COSPv3) in an independent population-based cohort, and to identify problem areas for IHC predictions. Histotype was abstracted from cancer registries for eligible ovarian carcinoma cases diagnosed from 2002 to 2011 in Alberta and British Columbia, Canada...
June 12, 2018: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29901522/expression-of-markers-of-m%C3%A3-llerian-clear-cell-carcinoma-in-primary-cervical-and-vaginal-gastric-type-adenocarcinomas
#20
Karen L Talia, Richard Wing-Cheuk Wong, W Glenn McCluggage
The incidence of cervical adenocarcinoma, both absolute and relative to squamous cell carcinoma, is increasing. Most cervical adenocarcinomas are human papillomavirus associated, although non-human papillomavirus-associated neoplasms exist; the latter include gastric-type adenocarcinoma (GAS) and clear cell carcinoma (CCC). Histologically, these 2 tumors may superficially resemble one other and although morphologic evaluation usually permits a correct diagnosis, immunohistochemistry may be required to resolve diagnostic uncertainty, especially in a small biopsy specimen...
June 12, 2018: International Journal of Gynecological Pathology
keyword
keyword
95675
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"